Ra Pharmaceuticals (NASDAQ:RARX) Downgraded by ValuEngine to Hold

ValuEngine cut shares of Ra Pharmaceuticals (NASDAQ:RARX) from a buy rating to a hold rating in a research report report published on Tuesday, ValuEngine reports.

A number of other research firms have also commented on RARX. SunTrust Banks lowered shares of Ra Pharmaceuticals from a buy rating to a hold rating in a report on Monday, October 14th. Royal Bank of Canada restated a sector perform rating and issued a $48.00 price objective on shares of Ra Pharmaceuticals in a research report on Friday, October 11th. Guggenheim cut shares of Ra Pharmaceuticals from a buy rating to a neutral rating in a research report on Thursday, November 7th. BMO Capital Markets downgraded shares of Ra Pharmaceuticals from an outperform rating to a market perform rating and set a $48.00 price objective for the company. in a research note on Thursday, October 10th. Finally, Jefferies Financial Group lowered shares of Ra Pharmaceuticals from a buy rating to a hold rating and set a $48.00 target price for the company. in a report on Thursday, October 10th. One analyst has rated the stock with a sell rating and thirteen have assigned a hold rating to the stock. Ra Pharmaceuticals presently has an average rating of Hold and a consensus target price of $45.36.

RARX stock traded up $0.17 during midday trading on Tuesday, hitting $47.00. The company had a trading volume of 402,072 shares, compared to its average volume of 643,933. The company has a current ratio of 25.73, a quick ratio of 25.73 and a debt-to-equity ratio of 0.01. Ra Pharmaceuticals has a 52 week low of $14.65 and a 52 week high of $47.35. The stock’s 50 day moving average price is $46.70 and its 200 day moving average price is $32.80. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -22.82 and a beta of 1.50.

Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). The firm had revenue of $3.00 million during the quarter. Analysts predict that Ra Pharmaceuticals will post -2.05 earnings per share for the current year.

In other Ra Pharmaceuticals news, insider Simon Read sold 10,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $25.41, for a total transaction of $254,100.00. Following the transaction, the insider now directly owns 16,234 shares of the company’s stock, valued at approximately $412,505.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Alonso Ricardo sold 2,285 shares of the company’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $46.70, for a total transaction of $106,709.50. Following the completion of the transaction, the insider now owns 6,858 shares of the company’s stock, valued at $320,268.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 44,070 shares of company stock worth $1,619,601. 4.30% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in RARX. Bank of Montreal Can lifted its holdings in Ra Pharmaceuticals by 218.0% in the second quarter. Bank of Montreal Can now owns 3,832 shares of the company’s stock worth $115,000 after buying an additional 2,627 shares during the period. Russell Investments Group Ltd. bought a new stake in Ra Pharmaceuticals during the 3rd quarter valued at approximately $115,000. Meeder Asset Management Inc. grew its holdings in shares of Ra Pharmaceuticals by 26.2% during the 3rd quarter. Meeder Asset Management Inc. now owns 6,209 shares of the company’s stock worth $147,000 after acquiring an additional 1,290 shares during the period. Marshall Wace LLP purchased a new position in shares of Ra Pharmaceuticals during the 1st quarter worth approximately $229,000. Finally, Virginia Retirement Systems ET AL grew its holdings in shares of Ra Pharmaceuticals by 12.9% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after acquiring an additional 1,200 shares during the period.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Put Option Volume

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.